申请人:Esteve Química, S.A.
公开号:EP2474548A1
公开(公告)日:2012-07-11
Preparation process of an antiviral drug and intermediates thereof
It comprises a preparation process of entecavir comprising: submitting a (1S,3R)-3-(tert-butyldimethylsilyloxy)-1-(oxiran-2-yl)pent-4-yn-1-ol (VIII) to a double esterification and to a radicalary cyclization, yielding a compound of formula (V), where either a compound of formula (VIII) is submitted to a first esterification reaction, then to a catalytic radicalary cyclization using titanocene dichloride as catalyst in the presence of Mn/2,4,6-collidine HCl or Zn/2,4,6-collidine/trimethylsilyl chloride, and finally to a second esterification reaction or, alternatively, the compound of formula (VIII) is submitted first to a catalytic radicalary cyclization, and then to an esterification reaction. Entecavir can be obtained by submitting compound (V) to a desilylation reaction to remove the TBS group and then to a Mitsunobu coupling with 2-amino-6-chloroguanine, followed by hydrolysis. It also relates to some new intermediates of the process.
抗病毒药物及其中间体的制备过程
本发明涉及一种恩替卡韦的制备过程,包括:将(1S,3R)-3-(叔丁基二甲基硅氧基)-1-(环氧丙烷-2-基)戊-4-炔-1-醇(VIII)进行双重酯化反应和自由基环化反应,得到公式(V)的化合物,其中化合物(VIII)先进行第一次酯化反应,然后使用二氯化钛作为催化剂,在Mn/2,4,6-共咪唑盐酸盐或Zn/2,4,6-共咪唑/三甲基氯硅烷的存在下进行催化自由基环化反应,最后进行第二次酯化反应;或者,另一种方法是将化合物(VIII)先进行催化自由基环化反应,然后进行酯化反应。恩替卡韦可以通过将化合物(V)进行去硅反应去除TBS基团,然后与2-氨基-6-氯鸟嘌呤进行Mitsunobu偶联反应,再经水解反应制得。本发明还涉及该过程中的一些新型中间体。